JP2017530132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530132A5 JP2017530132A5 JP2017516764A JP2017516764A JP2017530132A5 JP 2017530132 A5 JP2017530132 A5 JP 2017530132A5 JP 2017516764 A JP2017516764 A JP 2017516764A JP 2017516764 A JP2017516764 A JP 2017516764A JP 2017530132 A5 JP2017530132 A5 JP 2017530132A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- solid drug
- drug form
- phenyl
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 claims description 56
- 239000003814 drug Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 34
- 239000002552 dosage form Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- -1 methylethyl Chemical group 0.000 claims description 17
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 26
- 230000002378 acidificating effect Effects 0.000 description 8
- 239000012458 free base Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- BGLSLIDLBHRORL-UHFFFAOYSA-N 2,6-di(propan-2-yl)aniline;hydrochloride Chemical compound Cl.CC(C)C1=CC=CC(C(C)C)=C1N BGLSLIDLBHRORL-UHFFFAOYSA-N 0.000 description 2
- 206010000021 21-hydroxylase deficiency Diseases 0.000 description 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 2
- 230000001780 adrenocortical effect Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- PKKNCEXEVUFFFI-UHFFFAOYSA-N nevanimibe Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC1(C=2C=CC(=CC=2)N(C)C)CCCC1 PKKNCEXEVUFFFI-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055964P | 2014-09-26 | 2014-09-26 | |
| US62/055,964 | 2014-09-26 | ||
| US201462086153P | 2014-12-01 | 2014-12-01 | |
| US62/086,153 | 2014-12-01 | ||
| PCT/US2015/052338 WO2016049518A1 (en) | 2014-09-26 | 2015-09-25 | Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530132A JP2017530132A (ja) | 2017-10-12 |
| JP2017530132A5 true JP2017530132A5 (https=) | 2018-11-08 |
Family
ID=54291659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516764A Pending JP2017530132A (ja) | 2014-09-26 | 2015-09-25 | Ｎ−（２，６−ビス（１−メチルエチル）フェニル）−ｎ’−（（１−（４−（ジメチルアミノ）フェニル）シクロペンチル）メチル）尿素塩酸塩の固体薬物形態ならびにこれに関係する組成物、方法、およびキット |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9546135B2 (https=) |
| EP (1) | EP3197435A1 (https=) |
| JP (1) | JP2017530132A (https=) |
| CN (1) | CN107205941A (https=) |
| AU (2) | AU2015320358B2 (https=) |
| BR (1) | BR112017006287A2 (https=) |
| CA (1) | CA2962597A1 (https=) |
| MX (1) | MX2017003916A (https=) |
| WO (1) | WO2016049518A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| US20160287565A1 (en) * | 2015-04-06 | 2016-10-06 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| CN112441941B (zh) * | 2020-12-03 | 2022-08-02 | 浙江荣耀生物科技股份有限公司 | 一种1-(4-氨基苯基)环戊基甲腈的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015644A (en) * | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| JP2005068066A (ja) * | 2003-08-25 | 2005-03-17 | Air Water Chemical Inc | ２，６−ジイソプロピルアニリンの精製方法 |
| JP6018041B2 (ja) * | 2010-03-23 | 2016-11-02 | シガ・テクノロジーズ・インコーポレーテッド | Ｓｔ−２４６の多形型および調製方法 |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| CN106236741A (zh) * | 2012-03-22 | 2016-12-21 | 密歇根大学董事会 | 用于治疗异常肾上腺皮质细胞疾病的化合物和方法 |
-
2015
- 2015-09-25 EP EP15778492.7A patent/EP3197435A1/en not_active Withdrawn
- 2015-09-25 WO PCT/US2015/052338 patent/WO2016049518A1/en not_active Ceased
- 2015-09-25 AU AU2015320358A patent/AU2015320358B2/en not_active Expired - Fee Related
- 2015-09-25 US US14/866,212 patent/US9546135B2/en active Active
- 2015-09-25 BR BR112017006287A patent/BR112017006287A2/pt not_active Application Discontinuation
- 2015-09-25 JP JP2017516764A patent/JP2017530132A/ja active Pending
- 2015-09-25 CN CN201580063601.XA patent/CN107205941A/zh active Pending
- 2015-09-25 CA CA2962597A patent/CA2962597A1/en not_active Abandoned
- 2015-09-25 MX MX2017003916A patent/MX2017003916A/es unknown
-
2016
- 2016-12-06 US US15/370,980 patent/US10059660B2/en active Active
-
2019
- 2019-09-20 US US16/578,047 patent/US20200255372A1/en not_active Abandoned
-
2020
- 2020-04-27 AU AU2020202784A patent/AU2020202784A1/en not_active Abandoned
-
2021
- 2021-06-25 US US17/359,249 patent/US12151998B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103945848B (zh) | 被取代的喹唑啉酮的口服即释制剂 | |
| TWI724990B (zh) | 醫藥組合 | |
| JP2014515373A5 (https=) | ||
| CN105338977A (zh) | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 | |
| Kang et al. | In vivo evaluation of oral anti-tumoral effect of 3, 4-dihydroquinazoline derivative on solid tumor | |
| FI3429571T3 (fi) | Lsd1-inhibiittorien yhdistelmiä käytettäväksi kasvaintautien hoitamisessa | |
| JP2015512406A5 (https=) | ||
| JP2008535867A5 (https=) | ||
| TW201118082A (en) | Combinations of a PI3K inhibitor and a MEK inhibitor | |
| CN111035640B (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途 | |
| JP2012522837A5 (https=) | ||
| AU2016202594B2 (en) | Scheme for administering N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide | |
| JP2018519324A5 (https=) | ||
| JP5903433B2 (ja) | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ | |
| JP2020531463A5 (https=) | ||
| CN119486713A (zh) | 尼罗加司他治疗 | |
| JP2015514796A (ja) | ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体 | |
| JP2017530132A5 (https=) | ||
| TW201043225A (en) | Antitumour combination comprising AVE8062 and sorafenib | |
| JP2020536048A5 (https=) | ||
| JP2022540759A5 (https=) | ||
| RU2016116915A (ru) | Комбинация | |
| TW202114682A (zh) | Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物 | |
| RU2013149175A (ru) | Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы | |
| CA3151770A1 (en) | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |